Kane will advance strategic priorities and advance Solrikitug, its lead asset, in Phase II trials and prepare for Phase III.

Karuna Therapeutics: Investors: Alexis Smith 518-338-8990 [email protected] Media: Bob Josefsberg [email protected] 646-734-3584 Goldfinch Bio: Kyle Kuvalanka [email protected] ...

Karuna Therapeutics, Inc. Unaudited Consolidated Statements of Operations (in thousands, except share and per share data) Three Months Ended Year Ended December 31, December 31, ...

Karuna Therapeutics focuses on therapies to treat neurological conditions. The stock is up more than 52% over the past year. The company has, as of the fourth quarter, $1.1 billion in cash, it said.

Bristol Myers Squibb on Friday agreed to buy Karuna Therapeutics for $14 billion, gaining a promising new type of antipsychotic medicine to help power growth as patents on its older therapies ...

Drugmaker Bristol Myers BMY-0.83%decrease; red down pointing triangle Squibb reached a deal to buy neuroscience-drug developer Karuna Therapeutics for $14 billion. Under the terms, Bristol would ...

Analysts have provided the following ratings for Karuna Therapeutics (NASDAQ:KRTX) within the last quarter: These 12 analysts have an average price target of $281.25 versus the current price of ...

Karuna Therapeutics stock jumped 48% into record territory early Friday, after the biopharmaceutical company announced a $14 billion agreement to be bought by Bristol Myers Squibb.

Karuna Therapeutics. Karuna Therapeutics is a clinical-stage biotech headquartered in Boston, MA, founded back in July 2009 by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn.The company ...

Karuna Therapeutics, Inc. and GFB, LLC, assignee of the Goldfinch Bio assignment estate, today announced their entry into an exclusive license agreement under which Karuna will obtain global ...

Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal.

Over the past 3 months, 8 analysts have published their opinion on Karuna Therapeutics (NASDAQ:KRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with ...